To systematically review the efficacy of Xuebijing Injection combined with western medicine in the treatment of systemic inflammatory response syndrome(SIRS). In this study, CBM, CNKI, Wanfang, VIP, PubMed and EMbase databases were retrieved for clinical randomized controlled trials on the effect of Xuebijing Injection combined with western medicine in the treatment of SIRS from the establishment of the database to July 31, 2020. After screening, Meta-analysis was conducted by RevMan 5.3 software, trial sequential analysis was conducted by TSA 0.9.5.10 beta software, and the evidence quality level was evaluated by GRADEprofiler 3.6.1 software. Meta-analysis showed that Xuebijing Injection combined with western medicine could reduce white blood cell count(MD=-2.32, 95%CI[-2.44,-2.21], P<0.000 01), C-reactive protein count(MD=-22.70, 95%CI[-29.61,-15.79], P<0.000 01), APACHE Ⅱ score(MD=-2.15, 95%CI[-2.43,-1.87], P<0.000 01), tumor necrosis factor alpha count(SMD=-1.23, 95%CI[-1.48,-0.99], P<0.000 01) and interleukin-6 count(SMD=-0.92, 95%CI[-1.15,-0.69], P<0.000 01), improve treatment efficiency(RR=1.39, 95%CI[1.23, 1.56], P<0.000 01), reduce incidence of multiple organ dysfunction(RR=0.47, 95%CI[0.35, 0.64], P<0.000 01) and mortality(RR=0.22, 95%CI[0.13, 0.37], P<0.000 01), which were better than western medicine treatment alone. Trial sequential analysis showed that in terms of reducing the incidence of multiple organ dysfunction and C-reactive protein count, the cumulative Z value passed through the traditional threshold, TSA threshold and expected information value, and reached the required number of cases. GRADE evaluation showed that the level of evidence was low or very low. According to the findings, Xuebijing Injection combined with western medicine is effective in treating SIRS. However, as the low quality of the included studies may affect the reliability of the conclusion, more high-quality studies shall be included for further verification in the future, so as to provide better suggestions for clinical medication.

Download full-text PDF

Source
http://dx.doi.org/10.19540/j.cnki.cjcmm.20201102.501DOI Listing

Publication Analysis

Top Keywords

xuebijing injection
20
western medicine
20
injection combined
16
combined western
16
sequential analysis
12
medicine treatment
12
treatment systemic
8
systemic inflammatory
8
inflammatory response
8
trial sequential
8

Similar Publications

[Quality markers prediction of Xuebijing Injection based on fingerprint, network pharmacology and content determination].

Zhongguo Zhong Yao Za Zhi

September 2024

School of Pharmaceutical Sciences, Guizhou Medical University Guiyang 561113, China Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education),Guizhou Medical University Guiyang 550004, China State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University Guiyang 550004, China.

This study aimed to provide scientific evidence for predicting quality markers(Q-markers) of Xuebijing Injection by establishing high-performance liquid chromatography(HPLC) fingerprints of 25 batches of Xuebijing Injection and determining the contents of 9 major components, as well as conducting network pharmacology research. Thirty common peaks were identified by fingerprints of 25 batches of Xuebijing Injection samples, and 12 chromatographic peaks were determined, with similarity ranging from 0.970 to 0.

View Article and Find Full Text PDF

Xuebijing and somatostatin against acute pancreatitis: A systematic review and network pharmacology.

Medicine (Baltimore)

December 2024

Department of Pharmacy, Affiliated Hospital 2 of Nantong University, And First People's Hospital of Nantong City, Nantong, Jiangsu Province, P.R. China.

Background: Acute pancreatitis (AP) is a common pancreatic disease. Xuebijing injection (XBJ) combined with somatostatin in the treatment of AP is frequently used in clinical practice. There is, however, a lack of high-quality evidence-based evidence and network pharmacology to regard the therapeutic efficacy and pharmacological mechanisms.

View Article and Find Full Text PDF

Anti-sepsis effects of Dahuang Mudan decoction and its disassembled prescriptions.

J Ethnopharmacol

December 2024

School of Pharmacy, Second Military Medical University (Naval Medical University), Shanghai, 200433, China; The Center for Fungal Infectious Diseases Basic Research and Innovation of Medicine and Pharmacy, Ministry of Education, Shanghai, 200433, China. Electronic address:

Article Synopsis
  • Dahuang Mudan decoction (DMD) is a traditional Chinese medicine used to treat infectious diseases, and this study aims to evaluate its effects on septic mice and understand its mechanisms.
  • Various tests, including sepsis models and blood tests, showed that DMD and its components significantly improved survival rates and reduced organ damage in septic mice, similar to a positive control drug (Xuebijing injection).
  • The study concluded that DMD and its ingredients work by reducing inflammation and coagulation activation, suggesting a promising therapeutic potential for sepsis treatment.
View Article and Find Full Text PDF

Objective: This study utilized transcriptomic sequencing combined with cellular and animal models to explore the potential mechanisms of Xuebijing in treating sepsis-induced myocardial dysfunction, also known as sepsis-induced myocardial injury.

Methods: We investigated potential targets and regulatory mechanisms of XBJ injection using network pharmacology and RNA sequencing. The effects of XBJ on oxidative stress and apoptosis levels in human cardiac myocytes (AC16) and C57BL/6 mice exposed to lipopolysaccharide (LPS) were evaluated by Enzyme-Linked Immunosorbent Assay (ELISA), fluorescent probe, Fluorescent Quantitative Polymerase Chain Reaction (qPCR), Western Blot, Transmission Electron Microscopy, oxidative stress-related indicators detection kit, flow cytometry, and Immunohistochemistry (IHC).

View Article and Find Full Text PDF

Background: Both acute myocardial infarction (AMI) and its salvage treatment, venoarterial-extracorporeal membrane oxygenation (VA-ECMO), may lead to the production of proinflammatory cytokines and further aggravate tissue damage. Xuebijing (XBJ) may modulate cytokine production involved in the inflammatory response. We aimed to determine the efficacy of XBJ in cardiogenic shock patients on VA-ECMO.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!